100 Recruiting Studies Using Ipilimumab

Active clinical trials that use this intervention, sourced directly from the NIH registry.

Browse by condition

Trials Using Ipilimumab

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

📍 Hartford Healthcare — Hartford, Connecticut

Metastatic Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

📍 Dana Farber Cancer Institute — Boston, Massachusetts

Head and Neck Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

📍 Duke Cancer Institute — Durham, North Carolina

Melanoma Stage III

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

📍 Dana-Farber Cancer Institute — Boston, Massachusetts

Breast Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

📍 Mayo Clinic- Florida — Jacksonville, Florida

Mucosal Melanoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer

📍 M D Anderson Cancer Center — Houston, Texas

Metastatic Malignant Neoplasm in the Brain

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Nivolumab+Ipilimumab+RT in MSS mCRC

📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts

Metastatic Microsatellite Stable Colorectal Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

📍 M D Anderson Cancer Center — Houston, Texas

Clinical Stage III Cutaneous Melanoma AJCC v8

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

📍 Thomas Hospital — Fairhope, Alabama

Advanced Melanoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

📍 Brigham and Women's Hospital — Boston, Massachusetts

Acute Myeloid Leukemia

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Advanced Melanoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

📍 Moffitt Cancer Center — Tampa, Florida

Metastatic Urothelial Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

📍 City of Hope Comprehensive Cancer Center — Duarte, California

Locally Advanced Extraskeletal Myxoid Chondrosarcoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

📍 The Angeles Clinic — Los Angeles, California

Melanoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

📍 M D Anderson Cancer Center — Houston, Texas

Clinical Stage 0 Gastric Cancer AJCC v8

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

📍 UCSF Benioff Children's Hospital — San Francisco, California

Malignant Rhabdoid Tumor

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

📍 Research Site — Santa Rosa, California

Unresectable Pleural Mesothelioma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

📍 Children's Hospital of Alabama — Birmingham, Alabama

Recurrent Classic Hodgkin Lymphoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

📍 Local Institution - 0059 — Los Angeles, California

Metastatic Colorectal Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

📍 Exelixis Clinical Site #116 — La Jolla, California

Renal Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida

Merkel Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Pancreatic Adenocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma

📍 Abramson Cancer Center at University of Pennsylvania — Philadelphia, Pennsylvania

Melanoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida

Non Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

📍 Banner MD Anderson — Gilbert, Arizona

Colorectal Neoplasms

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Recurrent Squamous Cell Lung Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Stage III Cutaneous Melanoma AJCC v7

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska

Astrocytoma, IDH-Mutant, Grade 4

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

📍 City of Hope Comprehensive Cancer Center — Duarte, California

Bladder Small Cell Neuroendocrine Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

📍 Los Angeles General Medical Center — Los Angeles, California

Anal Canal Squamous Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

📍 Mobile Infirmary Medical Center — Mobile, Alabama

Locally Advanced Rectal Adenocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

📍 Memorial Sloan Kettering Cancer Center — New York, New York

Breast Neoplasm Female

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia

Cutaneous Melanoma, Stage III

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

📍 Duke Cancer Institute — Durham, North Carolina

Renal Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

📍 Emory University Hospital Midtown — Atlanta, Georgia

Squamous Cell Carcinoma of the Head and Neck

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients

📍 MD Anderson Cancer Center — Houston, Texas

ICB-refractory Melanoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

📍 Huntsman Cancer Institute — Salt Lake City, Utah

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

📍 Mayo Clinic — Rochester, Minnesota

Solid Tumor

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

📍 Dana Farber Cancer Institute — Boston, Massachusetts

Cutaneous Melanoma

View Study & Checklist ➔

ACTIVE_NOT_RECRUITING Phase3 💊 Investigational Drug / Biologic

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

📍 University of South Alabama Mitchell Cancer Institute — Mobile, Alabama

Clear Cell Renal Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

📍 M D Anderson Cancer Center — Houston, Texas

Bone Sarcoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

📍 Honor Health — Scottsdale, Arizona

Metastatic Uveal Melanoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC

📍 UC San Diego Moores Cancer Center — La Jolla, California

Advanced NSCLC

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

📍 Dana Farber Cancer Institute — Boston, Massachusetts

Kidney Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

📍 Dana-Farber Cancer Institute — Boston, Massachusetts

Advanced Malignant Solid Neoplasm

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

📍 National Cancer Institute Developmental Therapeutics Clinic — Bethesda, Maryland

Lymphoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

📍 Houston Methodist Hospital — Houston, Texas

B Cell Lymphoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Acinar Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

📍 University Health Network- Princess Margaret Cancer Centre — Toronto, Ontario

Melanoma (Skin)

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

📍 Local Institution - 0032 — Anchorage, Alaska

Non-Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

📍 Weill Cornell Medicine — New York, New York

Metastatic Prostate Neuroendocrine Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

📍 Greenebaum Comprehensive Cancer Center University of Maryland School of Medicine — Baltimore, Maryland

Mesothelioma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

📍 University of Chicago Medicine — Chicago, Illinois

Hodgkin Lymphoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

📍 City of Hope Medical Center — Duarte, California

Recurrent Glioblastoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona

Lung Adenocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Metastatic Large Cell Neuroendocrine Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

📍 Local Institution - 0013 — Washington D.C., District of Columbia

Renal Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Surgical Nivolumab And Ipilimumab For Recurrent GBM

📍 University of California Los Angeles — Los Angeles, California

Glioblastoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

📍 City of Hope Comprehensive Cancer Center — Duarte, California

Anatomic Stage III Breast Cancer AJCC v8

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery

📍 M D Anderson Cancer Center — Houston, Texas

Dedifferentiated Liposarcoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

📍 Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia

Melanoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

📍 Stanford University Medical Center — Stanford, California

Metastatic Soft-tissue Sarcoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

📍 University of South Alabama — Mobile, Alabama

Melanoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

📍 M D Anderson Cancer Center — Houston, Texas

Leukemia

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

📍 M D Anderson Cancer Center — Houston, Texas

Castration Levels of Testosterone

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

📍 Lancaster General Hospital — Lancaster, Pennsylvania

Metastatic Melanoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Axitinib + Ipilimumab in Advanced Melanoma

📍 Moffitt Cancer Center — Tampa, Florida

Melanoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

📍 Northwestern University — Evanston, Illinois

Prostate Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey

Melanoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

📍 Hartford Healthcare Alliance (Data Collection Only) — Hartford, Connecticut

Metastatic Melanoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

📍 Banner University Medical Center Tucson Campus — Tucson, Arizona

Solid Tumor

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer

📍 University of Chicago — Chicago, Illinois

Stage IV Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

📍 City of Hope Comprehensive Cancer Center — Duarte, California

Previously Treated Myelodysplastic Syndrome

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

📍 University of California, San Diego Moores Cancer Center — La Jolla, California

Renal Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

📍 Boston Children's Hospital — Boston, Massachusetts

Atypical Teratoid Rhabdoid Tumor

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

📍 MD Anderson in The Woodlands — Conroe, Texas

Lung Adenocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

📍 M D Anderson Cancer Center — Houston, Texas

ALK Gene Rearrangement

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Clinical Stage III Cutaneous Melanoma AJCC v8

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

📍 Local Institution - 0001 — Anchorage, Alaska

Urothelial Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

📍 Dana-Farber Cancer Institute — Boston, Massachusetts

Meningiomas

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC

📍 Johns Hopkins at Bayview Medical Center — Baltimore, Maryland

Non-Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania

Head and Neck Squamous Cell Carcinoma (HNSCC)

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona

Grade 2 Meningioma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

📍 University of California, San Diego Moores Cancer Center — La Jolla, California

Genitourinary Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Melanoma of Unknown Primary

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

📍 City of Hope Medical Center — Duarte, California

Clear Cell Renal Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Early Phase1 💊 Investigational Drug / Biologic

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

📍 M D Anderson Cancer Center — Houston, Texas

Clear Cell Renal Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

📍 M D Anderson Cancer Center — Houston, Texas

Aggressive Variant Prostate Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

📍 Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland

Colorectal Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

📍 Cedars Sinai Medical Center — Los Angeles, California

Breast Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

📍 Moffitt Cancer Center - McKinley Campus — Tampa, Florida

Clinical Stage III Cutaneous Melanoma AJCC v8

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer

📍 Massachusetts General Hospital — Boston, Massachusetts

Pancreatic Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

📍 Massachusetts General Hospital — Boston, Massachusetts

Microsatellite Stable Colorectal Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

📍 Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey

Bladder Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

📍 University of Illinois Chicago — Chicago, Illinois

Ovarian Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

📍 Yale University — New Haven, Connecticut

Recurrent B Acute Lymphoblastic Leukemia

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts

Papillary Renal Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

📍 City of Hope Comprehensive Cancer Center — Duarte, California

Differentiated Thyroid Gland Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Clinical Stage III Cutaneous Melanoma AJCC v8

View Study & Checklist ➔